DK0705278T3 - Apoptosehæmmer - Google Patents

Apoptosehæmmer

Info

Publication number
DK0705278T3
DK0705278T3 DK95909730T DK95909730T DK0705278T3 DK 0705278 T3 DK0705278 T3 DK 0705278T3 DK 95909730 T DK95909730 T DK 95909730T DK 95909730 T DK95909730 T DK 95909730T DK 0705278 T3 DK0705278 T3 DK 0705278T3
Authority
DK
Denmark
Prior art keywords
inhibiting
apo
compound
domain
carrier
Prior art date
Application number
DK95909730T
Other languages
Danish (da)
English (en)
Inventor
Peter Krammer
Michael Westendorp
Klaus Schulze-Osthoff
Klaus-Michael Debatin
Rainer Frank
Jens Dhein
Henning Walczak
Eckart Knipping
Kirstin Stricker
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19944412177 external-priority patent/DE4412177C1/de
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Application granted granted Critical
Publication of DK0705278T3 publication Critical patent/DK0705278T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DK95909730T 1994-04-08 1995-02-16 Apoptosehæmmer DK0705278T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19944412177 DE4412177C1 (de) 1994-04-08 1994-04-08 Hemmer von Apoptose

Publications (1)

Publication Number Publication Date
DK0705278T3 true DK0705278T3 (da) 2004-03-22

Family

ID=6514949

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95909730T DK0705278T3 (da) 1994-04-08 1995-02-16 Apoptosehæmmer

Country Status (8)

Country Link
US (1) US20070207160A1 (es)
EP (1) EP0705278B1 (es)
JP (2) JP3778453B2 (es)
AT (1) ATE255129T1 (es)
DE (1) DE4447484C2 (es)
DK (1) DK0705278T3 (es)
ES (1) ES2211899T3 (es)
WO (1) WO1995027735A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946255B1 (en) 1995-03-20 2005-09-20 Ko Okumura Monoclonal antibody reacting specifically reacting with Fas ligand and production process thereof
WO1996040041A2 (en) * 1995-06-07 1996-12-19 Chiron Corporation Antibodies to fas antigen capable of inhibiting apoptosis
US6096312A (en) * 1995-06-30 2000-08-01 Mochida Pharmaceutical Co., Ltd. Agent for suppressing a reduction of CD4+ lymphocytes
JPH09124509A (ja) * 1995-10-27 1997-05-13 Sumitomo Electric Ind Ltd 肝炎治療剤
DE19544333C2 (de) * 1995-11-28 1998-12-10 Deutsches Krebsforsch Verfahren zur Beurteilung der Aktivität von Arzneistoffen
AU2814897A (en) * 1996-04-25 1997-11-12 T Cell Sciences, Inc. Method of isolating regulators of t cell activation
GB9703276D0 (en) * 1997-02-17 1997-04-09 Screaton Gavin R Materials and methods relating to the protection of useful immune cells
JP2001521743A (ja) * 1997-10-30 2001-11-13 コーネル リサーチ ファウンデーション、インコーポレイティッド 組換えベクターに対する免疫応答の阻害方法
EP1447093A1 (en) * 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
ATE438662T1 (de) 2003-03-26 2009-08-15 Apogenix Gmbh Verbesserte fc-fusionsproteine
SI2428252T1 (sl) 2006-12-28 2015-01-30 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Nevtralizacija invazije aktivnostnih blokov cd95 v celicah glioblastoma in vivo
ES2524553T3 (es) 2008-06-17 2014-12-10 Apogenix Gmbh Receptores multiméricos de TNF
US11369572B2 (en) * 2009-07-21 2022-06-28 Queen Mary & Westfield College Fas (Apo-1,CD95) targeted platforms for intracellular drug delivery
WO2014013036A1 (en) 2012-07-18 2014-01-23 Apogenix Gmbh Inhibitors of the cd95 signaling pathway for treatment of mds
EP3076179A1 (en) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnosis and treatment of low grade gliomas
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
WO2018129332A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
JP2020503351A (ja) 2017-01-06 2020-01-30 アイオバンス バイオセラピューティクス，インコーポレイテッド カリウムチャネルアゴニストによる腫瘍浸潤リンパ球の増殖及びその治療的使用
US20200224161A1 (en) 2017-05-10 2020-07-16 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2019103857A1 (en) 2017-11-22 2019-05-31 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
EP3724885A2 (en) 2017-12-15 2020-10-21 Iovance Biotherapeutics, Inc. Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
EP3752600A1 (en) 2018-02-13 2020-12-23 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
CA3131305A1 (en) 2019-03-01 2020-09-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
JP2022521355A (ja) 2019-03-29 2022-04-06 ミスト セラピューティクス リミテッド ライアビリティ カンパニー Ｔ細胞治療薬を生成するためのエクスビボ方法ならびに関連する組成物および方法
IL293350A (en) 2019-11-27 2022-07-01 Myst Therapeutics Llc A method for producing tumor-reactive t cells using modulatory substances
KR20220158727A (ko) 2020-02-27 2022-12-01 미스트 쎄라퓨틱스, 엘엘씨 종양 반응성 t 세포의 생체외 농축 및 확장 방법 및 이의 관련 조성물
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486344A (en) * 1983-03-28 1984-12-04 Miles Laboratories, Inc. Urea-linked immunogens, antibodies, and preparative method
DK354487A (da) * 1986-07-11 1988-01-12 Noboru Yanaihara Oncogen-relaterede peptider
PT90657B (pt) * 1988-05-27 1995-03-01 Ortho Pharma Corp Processo para a preparacao de peptidos que bloqueiam a ligacao de hiv-1 a proteina cd4 receptora
JPH05506031A (ja) * 1990-03-30 1993-09-02 スミスクライン・ビーチャム・コーポレイション 免疫不全ウイルス感染に伴う疾病の抑制
DE69233441T2 (de) * 1991-04-26 2005-10-13 Osaka Bioscience Institute, Suita Menschliches Zelloberflächen-Antigen codierende DNA
JPH09503672A (ja) * 1993-10-14 1997-04-15 イミュネックス・コーポレーション Ｆａｓ拮抗剤とその利用
US5830469A (en) * 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof

Also Published As

Publication number Publication date
JP3778453B2 (ja) 2006-05-24
ES2211899T3 (es) 2004-07-16
EP0705278B1 (de) 2003-11-26
DE4447484C2 (de) 1997-07-17
ATE255129T1 (de) 2003-12-15
JP2004215669A (ja) 2004-08-05
US20070207160A1 (en) 2007-09-06
DE4447484A1 (de) 1995-10-26
JPH08511692A (ja) 1996-12-10
WO1995027735A1 (de) 1995-10-19
EP0705278A1 (de) 1996-04-10
JP3811745B2 (ja) 2006-08-23

Similar Documents

Publication Publication Date Title
DK0705278T3 (da) Apoptosehæmmer
DE60141347D1 (de) Zusammensetzungen zur beseitigung von unangenehmen gerüchen
ATE328090T1 (de) Varianten der cellulase, die egiii änhelt, und zusammensetzungen, die diese enthalten
DK0840732T3 (da) Substituerede benzolactamforbindelser som substans P-antagonister
ES2108120T3 (es) Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
NZ333475A (en) Microemulsion all purpose liquid cleaning compositions containing 0.05% to 5.0% of an acaricidal agent
MA26770A1 (fr) Diarylamines substituees par 1-heterocycle.
BR0313420A (pt) Quinolonas microbicidas, suas composições e usos
MX9601360A (es) Mezcla estabilizante sinergistica.
UA39099C2 (uk) Циклічні азотовмісні похідні, суміш їх ізомерів або окремі ізомери, або їх солі
DK1311482T3 (da) Ikke-imidazolaryloxypiperidiner som H3-receptorligander
NO992878L (no) Indolin-2-on-derivater, fremgangsmåte for fremstilling av dem og farmasöytiske blandinger som inneholder dem
TR200101961T2 (tr) 1,2-halkalı kinolin türevleri
ES2150489T3 (es) 1-amidinofenil-pirrolidonas, -piperidinonas, -azetinonas como inhibidores de la agregacion de plaquetas.
ATE191334T1 (de) Hydrophilierte zahnabdruckmassen
DE69224712D1 (de) Verschleissfeste, flammhemmende Zusammensetzungen
EA200300580A1 (ru) Соединения лактама
EA199700222A1 (ru) Сульфонилалканоиламиногидроксиэтиламиносульфонамид в качестве ингибиторов ретровирусной протеазы
HK1028568A1 (en) Alpha-ketoamide multicatalytic protease inhibitors
DE69908507D1 (de) Zusammensetzung zur Bekämpfung von schädlichen Arthropoden
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
JPS56156289A (en) Metal chelate of 1,4-bis(substituted amino)- 5,8-dihydroxyanthraquinone
ES2181366T3 (es) Derivados de piperidina que tienen efectos sobre sistemas relacionados con serotonina.
TR200002932T2 (tr) Azabisayklik 5HT1 Alıcı liganolları
ATE201204T1 (de) Derivate der thiazolidine-4-carbonsäure als cytoprotektive mittel